Compare CNXC & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNXC | TLX |
|---|---|---|
| Founded | 1991 | 2015 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.3B |
| IPO Year | N/A | N/A |
| Metric | CNXC | TLX |
|---|---|---|
| Price | $40.27 | $7.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $69.00 | $21.00 |
| AVG Volume (30 Days) | ★ 1.2M | 138.4K |
| Earning Date | 01-14-2026 | 01-15-2026 |
| Dividend Yield | ★ 3.60% | N/A |
| EPS Growth | ★ 54.10 | N/A |
| EPS | ★ 4.74 | 0.04 |
| Revenue | ★ $9,720,870,000.00 | $664,225,558.00 |
| Revenue This Year | $4.00 | N/A |
| Revenue Next Year | $3.16 | N/A |
| P/E Ratio | ★ $8.43 | $184.10 |
| Revenue Growth | 3.40 | ★ 55.35 |
| 52 Week Low | $31.63 | $7.72 |
| 52 Week High | $66.00 | $30.36 |
| Indicator | CNXC | TLX |
|---|---|---|
| Relative Strength Index (RSI) | 61.96 | 27.12 |
| Support Level | $38.40 | $7.72 |
| Resistance Level | $40.02 | $10.03 |
| Average True Range (ATR) | 1.27 | 0.27 |
| MACD | 0.61 | -0.18 |
| Stochastic Oscillator | 88.65 | 4.55 |
Concentrix Corp is a technology enabled company specialized in customer engagement and customer management. The company provides end-to-end capabilities, including CX process optimization, technology innovation and design engineering, front- and back-office automation, analytics and business transformation services to clients in five industry verticals. The Company's verticals are technology and consumer electronics, retail, travel and e-commerce, communications and media, banking, financial services and insurance, and healthcare. Geographically, the company operates in Philippines, Unites States, India, Frances and Others. Maximum revenue is from Technology and consumer electronics industry and geographically from Philippines.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.